26 June 2020
- Sienna relocates to 23 Normanby Road, Notting Hill.
- Sienna leaves the STC precinct after a successful 5 years.
- Development, commercialisation and launch of the hTERT IVD in the USA (2016)
- Successful registrations and l istings with the FDA, TGA and CE mark certifications
- Global expansion of our hTERT IVD distribution network (12 regions and counting)
- Successful IPO and listing with the ASX in 2017 (ASC:SDX)
- Acquisition of unique liquid biopsy and exosome isolation technology
ASX RELEASE
Change of Registered Office
Melbourne, Australia, 26 June 2020: Sienna Cancer Diagnostics (ASX: SDX) (“Sienna” or “the Company”) advises that effective from today, the principal and registered office of the Company has changed to:
23 Normanby Rd
Notting Hill, Victoria 3168
ENDS.
For Further Information, please contact:
Carl Stubbings, CEO & Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 9548 7586
The release of this announcement was authorised by Tony Di Pietro, Company Secretary.
